2 news items
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
ALNY
2 May 24
for its product candidates, including vutrisiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
ALNY
7 Apr 24
, including zilebesiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products
- Prev
- 1
- Next